Trial record 4 of 83 for:    resveratrol

The Cognitive and Cerebral Blood Flow Effects of Resveratrol

This study has been completed.
Sponsor:
Information provided by:
Northumbria University
ClinicalTrials.gov Identifier:
NCT01010009
First received: November 6, 2009
Last updated: May 17, 2012
Last verified: May 2012

November 6, 2009
May 17, 2012
June 2008
March 2009   (final data collection date for primary outcome measure)
  • Modulation of Levels of Total Haemoglobin [ Time Frame: 0-81 mins (absorption period=1- 45 mins , post dose period 46- 81 mins) ] [ Designated as safety issue: No ]
    This outcome measure provides the change from baseline values (in µmol/L) of total levels of haemoglobin during the 46-81 min post dose testing period. This was measured in the frontal cortex by near infrared spectroscopy (NIRS).
  • Modulation of Deoxygenated Levels of Haemoglobin [ Time Frame: 0-81 mins (absorption period=1- 45 mins , post dose period 46- 81 mins) ] [ Designated as safety issue: No ]
    This outcome measure provides the change from baseline values (in µmol/L) of levels of deoxygenated haemoglobin during the 46-81 min post dose testing period. This was measured in the frontal cortex by near infrared spectroscopy (NIRS).
Cerebral blood flow [ Time Frame: 115 mins ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01010009 on ClinicalTrials.gov Archive Site
Number of Participants With Significant Modulation of Cognitive Performance [ Time Frame: 46-81 mins post dose ] [ Designated as safety issue: No ]
This outcome measure assessed any significant modulation of cognitive task performance during the 46-81 min post dose period. The cognitive tasks utilized were cognitively demanding computer based, numerical tasks which assessed working memory. Significant modulation is defined as significant difference between baseline and post-dose task performance.
Cognitive performance [ Time Frame: 60 mins ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
The Cognitive and Cerebral Blood Flow Effects of Resveratrol
Effects of Resveratrol on Cerebral Blood Flow Parameters and Cognitive Performance in Humans: a Double-blind, Placebo-controlled, Crossover Investigation

Research shows that resveratrol is able to induce vasodilation (and therefore blood flow) by interacting with nitric oxide (NO). Research also shows that acute administration of metabolic substrates, like oxygen and glucose, can enhance aspects of cognitive performance in young, healthy humans. The aim of this investigation was to determine if the consumption of resveratrol could modulate cerebral blood flow and if this in turn could influence cognitive performance by increasing access to blood borne metabolic fuel. Results showed that compared to placebo, after consuming 500mg pure trans-resveratrol, levels of total haemoglobin were significantly higher in the frontal cortex of young, healthy participants during cognitive task completion. Cognitive performance was not effected.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Cognitive and Cerebral Blood Flow Effects of Resveratrol
  • Dietary Supplement: Trans- resveratrol
    All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
    Other Name: Transmax from Biotivia.
  • Other: Placebo (silica)
    All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
    Other Name: Pharmaceutical grade silica
  • Experimental: Resveratrol 250mg
    Interventions:
    • Dietary Supplement: Trans- resveratrol
    • Other: Placebo (silica)
  • Experimental: Resveratrol 500mg
    Interventions:
    • Dietary Supplement: Trans- resveratrol
    • Other: Placebo (silica)
  • Placebo Comparator: Placebo
    Interventions:
    • Dietary Supplement: Trans- resveratrol
    • Other: Placebo (silica)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
March 2009
March 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male/female,
  • Healthy
  • Age 18-35 years old
  • Non smoker
  • Proficient in English
  • Not taking any herbal or prescription medications
  • Not pregnant
  • Does not drink more than 6 cups of coffee per day

Exclusion Criteria:

  • Suffered a head injury, neurological disorder or neuro-developmental disorder
  • Food allergies/intolerances
Both
18 Years to 35 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01010009
22P2
No
Emma Wightman, Northumbria University
Northumbria University
Not Provided
Study Director: Crystal Haskell Northumbria University
Northumbria University
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP